{
  "id": 6116020,
  "title": "Clover reports positive Phase 2 respiratory combination vaccine trial in adults",
  "url": "https://urgent.news/2026/09/07/clover-reports-positive-phase-2-respiratory-combination-vaccine-trial",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-07T07:33:19.000Z",
  "source": {
    "name": "Vietnam Investment Review",
    "slug": "vietnam-investment-review",
    "url": "https://vir.com.vn/clover-reports-positive-phase-2-respiratory-combination-vaccine-trial-in-adults-160227.html"
  },
  "original_language": "en",
  "account": "Clover Biopharmaceuticals, Ltd. announced positive Phase 2 trial results for their protein-based RSV+hMPV±PIV3 respiratory vaccine candidates in older adults. The trial, conducted in Australia, involved 420 participants aged 60-85 years and showed antibody titers and neutralizing antibody increases in line with or higher than previous trials. The addition of PIV3 (PIV3) antigen in the triple vaccine (SCB-1033) did not reduce the effectiveness of the RSV+hMPV component. The vaccine showed no significant side effects and was generally well-tolerated with mild local and systemic adverse events. Clover's Trimer-Tag technology platform for multi-valent protein-based vaccines was validated in this study.",
  "summary": "Clover Biopharmaceuticals announced positive Phase 2 clinical trial results in Australia for its combination vaccine candidates targeting respiratory syncytial virus and human metapneumovirus in older adults",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}